Pembrolizumab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Pembrolizumab
Health Canada Patents

Veranova: A CDMO that manages complexity with confidence.

Contact Supplier

Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Contact Supplier

pharmacompass-1-m-2025-08-25

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Pembrolizumab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 3 Listed Suppliers

3 API Suppliers
3 Listed Suppliers

DEVELOPMENTS

3309 Drugs in Development

3309 Drugs in Development

FINISHED DOSAGE FORMULATIONS

41 FDF Dossiers, 1 FDA Orange Book, 2 Europe, 1 Canada, 36 Australia, 1 South Africa

41 FDF Dossiers
1 FDA Orange Book
2 Europe
1 Canada
36 Australia
1 South Africa

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 3 Kirsch Pharma, 4 Actylis, 1 BASF, 4 Gangwal Chemicals, 1 Nanjing Bold Chemical, 6 Seppic

1 Nanjing Well Pharmaceutical
2 Pfanstiehl
3 Kirsch Pharma
4 Actylis
1 BASF
4 Gangwal Chemicals
1 Nanjing Bold Chemical
6 Seppic

EXCIPIENTS BY APPLICATIONS

10 Solubilizers, 9 Parenteral, 5 Thickeners and Stabilizers, 3 Topical, 3 Surfactant & Foaming Agents, 3 Emulsifying Agents, 2 Film Formers & Plasticizers, 2 Taste Masking, 2 Coating Systems & Additives, 1 API Stability Enhancers, 1 Co-Processed Excipients, 1 Direct Compression, 1 Rheology Modifiers

10 Solubilizers
9 Parenteral
5 Thickeners and Stabilizers
3 Topical
3 Surfactant & Foaming Agents
3 Emulsifying Agents
2 Film Formers & Plasticizers
2 Taste Masking
2 Coating Systems & Additives
1 API Stability Enhancers
1 Co-Processed Excipients
1 Direct Compression
1 Rheology Modifiers

DIGITAL CONTENT

6 Data Compilation #PharmaFlow, 6 Stock Recap #PipelineProspector, 1258 News #PharmaBuzz

6 Data Compilation #PharmaFlow
6 Stock Recap #PipelineProspector
1258 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Regulatory FDF Prices, 11 Annual Reports

1 US Medicaid Prescriptions
1 Regulatory FDF Prices
11 Annual Reports

MARKET PLACE

4 APIs, 5 FDF Dossiers

4 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4Merck Canada Inc.

filter Patent Reset all filters

4 All

01 22691357

02 12830806

03 12937521

filter Product Reset all filters

4 All

01 4PEMBROLIZUMAB

filter Dosage Reset all filters

4 All

01 1POWDER FOR SOLUTION

02 3SOLUTION

filter Exp Date Reset all filters

4 All

01 22028-06-13

02 12032-03-29

03 12035-02-03

Product Main Page

01

Merck Canada Inc.

Pembrolizumab

Process Development

Not Confirmed

Merck Canada Inc.

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-06-13

Date Granted : 2014-09-23

Pembrolizumab

Brand Name : KEYTRUDA

Patent Number : 2691357

Filing Date : 2008-06-13

Strength per Unit : 50 mg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2028-06-13

Date Granted : 2014-09-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Merck Canada Inc.

Pembrolizumab

Process Development

Not Confirmed

Merck Canada Inc.

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-06-13

Date Granted : 2014-09-23

Pembrolizumab

Brand Name : KEYTRUDA

Patent Number : 2691357

Filing Date : 2008-06-13

Strength per Unit : 25 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2028-06-13

Date Granted : 2014-09-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Merck Canada Inc.

Pembrolizumab

Process Development

Not Confirmed

Merck Canada Inc.

Country

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-03-29

Date Granted : 2020-05-12

Pembrolizumab

Brand Name : KEYTRUDA

Patent Number : 2830806

Filing Date : 2012-03-29

Strength per Unit : 25 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2032-03-29

Date Granted : 2020-05-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Merck Canada Inc.

Pembrolizumab

Process Development

Not Confirmed

Merck Canada Inc.

Country

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-02-03

Date Granted : 2023-08-29

Pembrolizumab

Brand Name : KEYTRUDA

Patent Number : 2937521

Filing Date : 2015-02-03

Strength per Unit : 25 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2035-02-03

Date Granted : 2023-08-29

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!